A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2013.04.029
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Improving Bone Health in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: Results of a Randomized Phase 2 Trial

Cancer
Cancer ResearchOncology
2017English

Bone Mineral Density Changes on Androgen Deprivation Therapy for Prostate Cancer and Response to Antiresorptive Therapy

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2005English

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

Clinical Cancer Research
Cancer ResearchOncology
2016English

Androgen Deprivation Therapy for Prostate Cancer

2017English

Effects of Androgen-Deprivation Therapy on Hypercoagulability in Prostate Cancer Patients: A Prospective, Longitudinal Study

Canadian Urological Association Journal
Urology
2017English

A Phase II Trial of Docetaxel and Erlotinib as First-Line Therapy for Elderly Patients With Androgen-Independent Prostate Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2007English

Risk of Ischemic Stroke in Patients With Prostate Cancer Receiving Androgen Deprivation Therapy in Taiwan

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2016English

Androgen Deprivation Therapy as Backbone Therapy in the Management of Prostate Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy